Case selection
. | SNEHD no. . | Eligible for current study, no. (%*) . | Outcome data available, no. (%†) . | Depcat available, no. (%†) . |
|---|---|---|---|---|
| All cases | 531 | 461 (87*) | 437 (95†) | 312 (68†) |
| Age group | ||||
| 16 to 34 y | 259 | 236 (91) | 227 (96) | 171 (72) |
| 35 to 49 y | 106 | 88 (83) | 83 (94) | 59 (67) |
| 50 y or older | 166 | 137 (83) | 127 (93) | 82 (60) |
| Sex | ||||
| Male | 296 | 254 (86) | 240 (94) | 163 (64) |
| Female | 235 | 207 (88) | 197 (95) | 149 (72) |
| Histologic subtype | ||||
| MCHL | 125 | 105 (84) | 101 (96) | 68 (65) |
| LDHL | 5 | 3 (60) | 2 (67) | 2 (67) |
| NSHL | 358 | 320 (89) | 305 (95) | 227 (71) |
| LRCHL | 16 | 16 (100) | 15 (94) | 5 (31) |
| cHL NOS | 27 | 17 (63) | 14 (82) | 10 (59) |
| EBV status‡ | ||||
| EBV positive | NA | 154 | 145 (94) | 101 (66) |
| EBV negative | NA | 307 | 292 (95) | 211 (69) |
. | SNEHD no. . | Eligible for current study, no. (%*) . | Outcome data available, no. (%†) . | Depcat available, no. (%†) . |
|---|---|---|---|---|
| All cases | 531 | 461 (87*) | 437 (95†) | 312 (68†) |
| Age group | ||||
| 16 to 34 y | 259 | 236 (91) | 227 (96) | 171 (72) |
| 35 to 49 y | 106 | 88 (83) | 83 (94) | 59 (67) |
| 50 y or older | 166 | 137 (83) | 127 (93) | 82 (60) |
| Sex | ||||
| Male | 296 | 254 (86) | 240 (94) | 163 (64) |
| Female | 235 | 207 (88) | 197 (95) | 149 (72) |
| Histologic subtype | ||||
| MCHL | 125 | 105 (84) | 101 (96) | 68 (65) |
| LDHL | 5 | 3 (60) | 2 (67) | 2 (67) |
| NSHL | 358 | 320 (89) | 305 (95) | 227 (71) |
| LRCHL | 16 | 16 (100) | 15 (94) | 5 (31) |
| cHL NOS | 27 | 17 (63) | 14 (82) | 10 (59) |
| EBV status‡ | ||||
| EBV positive | NA | 154 | 145 (94) | 101 (66) |
| EBV negative | NA | 307 | 292 (95) | 211 (69) |
SNEHD indicates Scotland and Newcastle Epidemiological study of Hodgkin's Disease; MCHL, mixed cellularity Hodgkin lymphoma; LDHL, lymphocyte depleted Hodgkin lymphoma; NSHL, nodular sclerosis Hodgkin lymphoma; LRCHL, lymphocyte-rich classic Hodgkin lymphoma; NOS, not otherwise specified; and NA, not applicable.
Percent of SNEHD case series.
Percent of eligible cases.
EBV status of Hodgkin and Reed-Sternberg cells.